IMNN

Company Overview — What Does Imunon, Inc. Do?

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey. Imunon, Inc. (IMNN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Corinne L. Goff and employs approximately 30 people, headquartered in LAWRENCEVILLE, New Jersey. With a market capitalization of $10M, IMNN is one of the notable companies in the Healthcare sector.

Imunon, Inc. (IMNN) Stock Rating — Reduce (April 2026)

As of April 2026, Imunon, Inc. receives a Reduce rating with a composite score of 26.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IMNN ranks #3,628 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Imunon, Inc. ranks #589 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IMNN Stock Price and 52-Week Range

Imunon, Inc. (IMNN) currently trades at $3.03. The stock lost $0.03 (1.0%) in the most recent trading session. The 52-week high for IMNN is $9.42, which means the stock is currently trading -67.8% from its annual peak. The 52-week low is $0.37, putting the stock 718.9% above its annual trough. Recent trading volume was 13K shares, suggesting relatively thin trading activity.

Is IMNN Overvalued or Undervalued? — Valuation Analysis

Imunon, Inc. (IMNN) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.73x, versus the sector average of 2.75x.

At current multiples, Imunon, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Imunon, Inc. Profitability — ROE, Margins, and Quality Score

Imunon, Inc. (IMNN) earns a quality factor score of 13/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -214.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -123.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IMNN Debt, Balance Sheet, and Financial Health

Imunon, Inc. has a debt-to-equity ratio of 74.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.32x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $5M.

IMNN has a beta of 2.07, meaning it is more volatile than the broader market — a $10,000 investment in IMNN would be expected to move 106.9% more than the S&P 500 on any given day. The stability factor score for Imunon, Inc. is 13/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Imunon, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Imunon, Inc. reported revenue of $0 and earnings per share (EPS) of $-6.83. Net income for the quarter was $-15M. Operating income came in at $-15M.

In FY 2025, Imunon, Inc. reported revenue of $0 and earnings per share (EPS) of $-6.83. Net income for the quarter was $-14M. Operating income came in at $-15M.

In Q3 2025, Imunon, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.16. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q2 2025, Imunon, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.15. Net income for the quarter was $-3M. Operating income came in at $-3M.

Over the past 8 quarters, Imunon, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing IMNN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IMNN Dividend Yield and Income Analysis

Imunon, Inc. (IMNN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IMNN Momentum and Technical Analysis Profile

Imunon, Inc. (IMNN) has a momentum factor score of 52/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 40/100 reflects moderate short selling activity.

IMNN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Imunon, Inc. (IMNN) ranks #589 out of 838 stocks based on the Blank Capital composite score. This places IMNN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IMNN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IMNN vs S&P 500 (SPY) comparison to assess how Imunon, Inc. stacks up against the broader market across all factor dimensions.

IMNN Next Earnings Date

No upcoming earnings date has been announced for Imunon, Inc. (IMNN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IMNN? — Investment Thesis Summary

The quantitative profile for Imunon, Inc. suggests caution. The quality score of 13/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. High volatility (stability score 13/100) increases portfolio risk.

In summary, Imunon, Inc. (IMNN) earns a Reduce rating with a composite score of 26.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IMNN stock.

Related Resources for IMNN Investors

Explore more research and tools: IMNN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IMNN head-to-head with peers: IMNN vs AZN, IMNN vs SLGL, IMNN vs VMD.